Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Late Relapse Ovarian Cancer
NCT02891824Phase 3Completed
- Sponsor
- ARCAGY
- Start
- Sep 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Placebo + Bevacizumab + Chemo with Atezolizumab + Bevacizumab + Chemo (2 arms). Primary endpoint: Progression-Free Survival at 19 months. Started Sep 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02891824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891824.